Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update-Reference-Cited by-同舟云学术

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update

Published:2024-09 Issue: Volume:198 Page:110381
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Hudson John M.^ORCID,Loblaw Andrew^ORCID,McGuffin Merrylee,Chung Hans T.^ORCID,Tseng Chia-Lin,Helou Joelle,Cheung Patrick,Szumacher Ewa,Liu Stanley^ORCID,Zhang Liying^ORCID,Deabreu Andrea,Mamedov Alexandre^ORCID,Morton Gerard^ORCID

Funder

Canadian Association of Radiation Oncology

Publisher

Elsevier BV

Reference40 articles.

1. Ultrahypofractionated radiotherapy for localised prostate cancer: how far can we go?;Corkum;Clin Oncol,2022

2. High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis;Anderson;J Contemp Brachytherapy,2021

3. Prostate cancer: 12. the economic burden;Grover;CMAJ Canadian Medical Association Journal,1999

4. The economic burden of prostate cancer;Roehrborn;BJU International,2011

5. High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results;Prada;Brachytherapy,2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiobiological meta-analysis of the response of prostate cancer to high dose rate brachytherapy;2024-07-14